Prominent publications by David Alan Isenberg

KOL Index score: 18932

OBJECTIVE: The importance of interleukin-17 (IL-17) is underscored both by its resistance to control by Treg cells and the propensity of Treg cells to produce this highly inflammatory cytokine. This study sought to address whether Th17 cells are inhibited by Treg cells in rheumatoid arthritis (RA) patients responding to anti-tumor necrosis factor (anti-TNF) therapy, and if so defining the underlying mechanisms of suppression.

METHODS: Inhibition of Th17 cell responses was determined by ...

Known for Treg Cells |  Th17 Cell |  Rheumatoid Arthritis |  Necrosis Factor |  Adalimumab Therapy
KOL Index score: 18469

INTRODUCTION: The current mainstay of the treatment of thrombotic antiphospholipid syndrome (APS) is long-term anticoagulation with vitamin K antagonists (VKAs) such as warfarin. Non-VKA oral anticoagulants (NOACs), which include rivaroxaban, have been shown to be effective and safe compared with warfarin for the treatment of venous thromboembolism (VTE) in major phase III prospective, randomized controlled trials (RCTs), but the results may not be directly generalizable to patients with ...

Known for Rivaroxaban Warfarin |  Antiphospholipid Syndrome |  Patients Aps |  Previous Vte |  Treatment Venous Thromboembolism
KOL Index score: 16204

OBJECTIVES: Evaluate efficacy and safety of tabalumab, a human IgG4 monoclonal antibody that binds and neutralises membrane and soluble B-cell activating factor (BAFF) versus placebo plus standard of care (SoC) in patients with systemic lupus erythematosus (SLE).

METHODS: This phase III, 52-week study randomised 1164 patients with moderate-to-severe SLE (Safety of Estrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index ≥6 at baseline). Patients received SoC plus ...

Known for Phase Iii |  Monoclonal Antibodies |  Tabalumab Placebo |  Subcutaneous Lupus Erythematosus |  120 Q4w
KOL Index score: 16081

INTRODUCTION: Currently available clinical assays to detect antiphospholipid antibodies (aPL) test for IgG and IgM antibodies to cardiolipin (aCL) and β2-glycoprotein I (aβ2GPI). It has been suggested that testing for IgA aPL and for antibodies to Domain I (DI), which carries the key antigenic epitopes of β2GPI, could add value to these current tests. We performed an observational, multicenter cohort study to evaluate the utility of IgG, IgM and IgA assays to each of CL, β2GPI and DI in ...

Known for Aps Igg |  Antiphospholipid Syndrome |  Igm Iga |  Anticardiolipin Antibodies |  Glycoprotein Aβ2gpi
KOL Index score: 15399

OBJECTIVE: To determine the prevalence of anti-high-density lipoprotein (anti-HDL) antibodies and to establish a possible relationship between anti-HDL, anticardiolipin antibodies (aCL), anti-beta(2)-glycoprotein I (anti-beta(2)GPI), and paraoxonase (PON) activity in patients with systemic lupus erythematosus (SLE) and primary antiphospholipid syndrome (APS).

METHODS: Thirty-two patients with SLE and 36 with primary APS were enrolled in a cross-sectional study. Twenty age- and ...

Known for Pon Activity |  Patients Sle |  Lupus Erythematosus |  High‐density Lipoprotein |  Primary Aps
KOL Index score: 15041

We have previously demonstrated that interleukin-6 (IL-6) increases the levels of the heat shock protein 90 (Hsp-90) and activates the Hsp-90beta promoter via the IL-6-activated transcription factors NF-IL6 and signal transducer and activator of transcription-3 (STAT-3). Here, we show that interferon-gamma (IFN-gamma) treatment increases the levels of Hsp-70 and Hsp-90 and also enhances the activity of the Hsp-70 and Hsp-90beta promoters with these effects being dependent on activation ...

Known for Signal Transducer |  Heat Shock |  Stat3 Hsf1 |  Stat1 Transcription |  Binding Proteins
KOL Index score: 14879

OBJECTIVE: To develop response criteria for juvenile dermatomyositis (DM).

METHODS: We analyzed the performance of 312 definitions that used core set measures from either the International Myositis Assessment and Clinical Studies Group (IMACS) or the Paediatric Rheumatology International Trials Organisation (PRINTO) and were derived from natural history data and a conjoint analysis survey. They were further validated using data from the PRINTO trial of prednisone alone compared to ...

Known for Major Clinical |  Core Measures |  Juvenile Dermatomyositis |  Rheumatology International |  Response Criteria
KOL Index score: 14433

The levels of the 90 kDa heat-shock protein (hsp90) and the activity of the hsp90beta gene promoter are increased in response to treatment by interleukin (IL)-6. The hsp90beta gene promoter contains binding sites for the transcription factors nuclear factor IL-6 (NF-IL6) and signal transducer and activator of transcription 3 (STAT-3), which are activated respectively by the mitogen-activated-protein-kinase and Jak-kinase pathways following IL-6 treatment. Both these factors can activate ...

Known for Heat Shock |  Signal Transducer |  Nuclear Factor |  Stat3 Transcription |  Binding Proteins
KOL Index score: 13646
Known for Myositis Assessment |  Inclusion Body |  Short Form |  Global Activity |  Quantitative Muscle Testing
KOL Index score: 13626

OBJECTIVES: To investigate the clinical and immunogenetic aspects of antibody formation against Ro/SSA and La/SSB as well as their linear B cell epitopes in patients with primary Sjögren's syndrome (pSS) from different European countries.

PATIENTS AND METHODS: Ninety patients with pSS from six European centres were studied. Serum samples from all patients were tested in a control laboratory for anti-Ro/SSA and anti-La/SSB autoantibodies by RNA precipitation assay and autoantibodies to ...

Known for Patients Autoantibodies |  Autoantibody Production |  Cell Epitopes |  Ssa Ssb |  Primary Sjögren
KOL Index score: 13616

OBJECTIVE: To investigate the ability of anti-endothelial cell antibodies (AECA) to modulate endothelial cell function.

METHODS: The effects of purified IgG from 11 patients with systemic lupus erythematosus (SLE) and 4 patients with systemic vasculitis on the expression of adhesion molecules (intercellular adhesion molecule 1, vascular cell adhesion molecule 1, E-selectin) by human umbilical vein endothelial cells and on the adhesion of the human promyelocytic cell line U937 were ...

Known for Systemic Vasculitis |  Endothelial Cell |  Leukocyte Adhesion |  Aeca Patients |  Vascular Humans
KOL Index score: 13613

BACKGROUND AND AIMS: We studied damage accrual and factors determining development and progression of damage in an international cohort of systemic lupus erythematosus (SLE) patients.

METHODS: The Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort recruited patients within 15 months of developing four or more 1997 American College of Rheumatology (ACR) criteria for SLE; the SLICC/ACR damage index (SDI) was measured annually. We assessed relative rates of ...

Known for Inception Cohort |  Damage Accrual |  Systemic Lupus |  International Collaborating |  Sle Slicc


David Alan Isenberg: Influence Statistics

Sample of concepts for which David Alan Isenberg is among the top experts in the world.
Concept World rank
52 weeks placebo #1
igg adi vivo #1
assessment bilag #1
illness lupus erythematosus #1
zinc fingers polymerase #1
serum baff levels #1
levels antiapo #1
arthritis‐prone mrl #1
ab2gpi adi #1
lupus patients patients #1
address lte atacicept #1
il6 anaemia #1
pga sfi #1
sle ids beg #1
rtp sle patients #1
clinical manifestations baseline #1
lymphocyte responses defects #1
tissuebound immunoglobulins #1
international study nonadherence #1
joint involvement presence #1
epru #1
analysis 276 patients #1
sle cardiovascular event #1
sle 5 #1
2 years sle #1
fenebrutinib week #1
np disease sle #1
autoantigens western cloning #1
refractory sle bcdt #1
intravenous treatment iscalimab #1
future damage #1
brf model #1
3 indices #1
subclass predominance #1
time sle patients #1
clinics inception #1
btz rtx #1
ungal predictor #1
cohort adverse events #1
immunophentyping #1
bcdt antidsdna antibodies #1
dialysis rtp medication #1
33h11 #1
9g4 levels #1
secreting clones #1
lupus activity indices #1
depletion bcd #1
monoclonal publication antibodies #1
8310 patients #1
wri 176 beta #1

Key People For Systemic Lupus Erythematosus

Top KOLs in the world
David Alan Isenberg
systemic lupus erythematosus patients sle rheumatoid arthritis
Michelle A Petri
systemic lupus erythematosus lupus nephritis patients sle
D Gladman Gladman
psoriatic arthritis systemic lupus erythematosus patients psa
Murray B Urowitz
systemic lupus erythematosus patients sle lupus nephritis
James F Fries
rheumatoid arthritis physical function systemic lupus erythematosus
Norman Talal
sex hormones lupus erythematosus sjögrens syndrome

David Alan Isenberg:Expert Impact

Concepts for whichDavid Alan Isenberghas direct influence:Systemic lupus erythematosus,  Lupus erythematosus,  Systemic lupus,  Patients sle,  Rheumatoid arthritis,  Sle patients,  Lupus nephritis,  Erythematosus systemic.

David Alan Isenberg:KOL impact

Concepts related to the work of other authors for whichfor which David Alan Isenberg has influence:Systemic lupus erythematosus,  Lupus nephritis,  Rheumatoid arthritis,  Sle patients,  Autoimmune diseases,  Antiphospholipid syndrome,  Regulatory cells.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom | University College London, UK. | Department of Rheumatology, Division of Medicine, University College London, London | Rheumatology, University College

FREE Custom List